Brokerages Set Bio-Techne Corp (NASDAQ:TECH) PT at $70.57

Shares of Bio-Techne Corp (NASDAQ:TECH) have been assigned a consensus rating of “Moderate Buy” from the sixteen ratings firms that are currently covering the company, Marketbeat Ratings reports. Two investment analysts have rated the stock with a sell recommendation, four have given a hold recommendation, nine have assigned a buy recommendation and one has assigned a strong buy recommendation to the company. The average 12-month target price among brokerages that have covered the stock in the last year is $70.5714.

A number of brokerages recently issued reports on TECH. Argus lifted their price objective on shares of Bio-Techne from $65.00 to $68.00 and gave the company a “buy” rating in a research note on Thursday, November 20th. Zacks Research cut Bio-Techne from a “hold” rating to a “strong sell” rating in a report on Wednesday, December 17th. Wells Fargo & Company upped their price objective on Bio-Techne from $59.00 to $70.00 and gave the stock an “overweight” rating in a research report on Thursday, November 6th. Benchmark reiterated a “buy” rating on shares of Bio-Techne in a research report on Tuesday. Finally, Citigroup reissued a “buy” rating on shares of Bio-Techne in a research note on Wednesday.

Key Bio-Techne News

Here are the key news stories impacting Bio-Techne this week:

• Positive Sentiment: Q2 results beat consensus — adjusted EPS $0.46 vs. $0.43 expected and revenue $295.9M vs. $290.2M; operating margin expanded ~244 bps, driven by cost and mix improvements. This explains much of the bullish price action. Read More.
• Positive Sentiment: Management guided to mid‑single‑digit underlying growth for fiscal 2026, with margin expansion and normalization of its cell‑therapy business highlighted as catalysts for accelerating growth — a forward-looking signal that helped lift sentiment. Read More.
• Positive Sentiment: Analyst support: Citi’s Patrick Donnelly kept a Buy rating with an $80 price target, reinforcing buy‑side confidence after the quarter. Read More.
• Neutral Sentiment: Board declared the quarterly dividend of $0.08/share (yield ~0.5%); ex‑dividend Feb 13, payable Feb 27 — modest income return but not a major driver. Read More.
• Neutral Sentiment: Full earnings/FAQ details are in the Q2 earnings call transcript for investors wanting color on product trends and operations. Read More.
• Neutral Sentiment: Reports flagged an anomalous short‑interest data point showing no meaningful short position reported recently — appears inconclusive and not a driver of the move.
• Negative Sentiment: Organic revenue was essentially flat (reported revenue down ~0.4% YoY), so the beat reflected margin and mix improvement rather than a clear reacceleration in top‑line demand — a risk if margin gains are temporary. Read More.
• Negative Sentiment: Valuation remains rich (P/E ~140 on recent data), so upside depends on sustained margin leverage and growth execution; disappointment would likely pressure the stock.

Institutional Inflows and Outflows

Several institutional investors have recently modified their holdings of TECH. Blue Trust Inc. grew its position in Bio-Techne by 109.7% during the 3rd quarter. Blue Trust Inc. now owns 453 shares of the biotechnology company’s stock worth $25,000 after acquiring an additional 237 shares during the last quarter. Danske Bank A S acquired a new stake in shares of Bio-Techne during the fourth quarter valued at about $29,000. eCIO Inc. bought a new stake in shares of Bio-Techne during the fourth quarter worth about $30,000. Allworth Financial LP increased its stake in shares of Bio-Techne by 68.1% in the second quarter. Allworth Financial LP now owns 612 shares of the biotechnology company’s stock valued at $31,000 after buying an additional 248 shares during the period. Finally, Measured Wealth Private Client Group LLC bought a new position in Bio-Techne in the 3rd quarter valued at approximately $32,000. 98.95% of the stock is currently owned by institutional investors and hedge funds.

Bio-Techne Stock Performance

TECH opened at $68.67 on Thursday. The company has a debt-to-equity ratio of 0.15, a current ratio of 4.22 and a quick ratio of 2.81. The business has a fifty day simple moving average of $63.23 and a 200 day simple moving average of $59.21. Bio-Techne has a 1 year low of $46.01 and a 1 year high of $79.28. The company has a market capitalization of $10.70 billion, a PE ratio of 140.15, a price-to-earnings-growth ratio of 4.46 and a beta of 1.48.

Bio-Techne (NASDAQ:TECH) last issued its quarterly earnings results on Wednesday, February 4th. The biotechnology company reported $0.46 EPS for the quarter, topping analysts’ consensus estimates of $0.43 by $0.03. Bio-Techne had a return on equity of 13.59% and a net margin of 6.41%.The company had revenue of $295.88 million for the quarter, compared to analysts’ expectations of $290.20 million. During the same quarter last year, the business earned $0.42 earnings per share. Bio-Techne’s revenue was down .4% on a year-over-year basis. Research analysts expect that Bio-Techne will post 1.67 EPS for the current year.

Bio-Techne Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Friday, February 27th. Shareholders of record on Monday, February 16th will be given a $0.08 dividend. The ex-dividend date is Friday, February 13th. This represents a $0.32 dividend on an annualized basis and a yield of 0.5%. Bio-Techne’s dividend payout ratio (DPR) is currently 65.31%.

Bio-Techne Company Profile

Bio-Techne Corporation (NASDAQ:TECH) is a global life sciences company that develops, manufactures and sells high-quality reagents, instruments and services for the research, diagnostic and bioprocessing markets. Its core product offerings include recombinant proteins, antibodies, immunoassays, nucleic acid probes and kits, single-cell analysis solutions and automated protein analysis systems. Flagship brands such as R&D Systems, Novus Biologicals, ProteinSimple and Advanced Cell Diagnostics provide researchers and clinicians with reliable tools for cell biology, immunology, proteomics and genomics applications.

Headquartered in Minneapolis, Minnesota, Bio-Techne serves customers across North America, Europe and the Asia-Pacific region through a combination of direct sales, distributors and strategic partnerships.